Buyout + growth fund research profile
CVC is an active India private-equity investor with a financial-services and healthcare footprint, supported by a global value-creation platform. Its India team has used control positions to professionalize businesses and pursue expansion before exit.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
CVC Capital (India) uses a buyout + growth approach across Health, consumer, fin services.
Current evidence
CVC closed Asia VI at $6.8 billion in 2024 and subsequently acquired a stake in Aavas Financiers, with the transaction completed in March 2025; CVC also announced the sale of its majority stake in HealthCare Global Enterprises to KKR. Aavas disclosures identify Siddharth Patel, Nikhil Gahrotra and Neha Sureka in the India-related governance record.
Strategy
Buyout + growth
Sector focus
Health, consumer, fin services
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
CVC closed Asia VI at $6.8 billion in 2024 and subsequently acquired a stake in Aavas Financiers, with the transaction completed in March 2025; CVC also announced the sale of its majority stake in HealthCare Global Enterprises to KKR. Aavas disclosures identify Siddharth Patel, Nikhil Gahrotra and Neha Sureka in the India-related governance record.
Investor questions
CVC Capital (India) is covered in Rupeia's private equity research universe. The current public record describes the strategy as Buyout + growth, with a sector focus of Health, consumer, fin services. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to CVC Capital (India) in the reviewed public sources: Aavas Financiers, HealthCare Global Enterprises, Sajjan India, UnitedLex, OANDA. It does not represent a complete current portfolio unless the manager has published one.
CVC announced the sale of up to 54% of Healthcare Global Enterprises to KKR after a 2020 investment and described revenue growth, KPI improvement, acquisitions and digital transformation during ownership. India fund-level IRR is not disclosed in the reviewed record. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: CVC Asia VI was reported at approximately $6.8B; India vehicle-level size is not separately disclosed.. Public terms or access information: Buyout and growth investing across financial services, healthcare, consumer and related sectors. The reviewed sources do not disclose standard India cheque sizes or reserve policy.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Siddharth Patel, Nikhil Gahrotra, Neha Sureka. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: India-specific deployment and Aavas transaction structure require periodic re-verification..
2025: CVC closed Asia VI at $6.8 billion in 2024 and subsequently acquired a stake in Aavas Financiers, with the transaction completed in March 2025; CVC also announced the sale of its majority stake in HealthCare Global Enterprises to KKR. Aavas disclosures identify Siddharth Patel, Nikhil Gahrotra and Neha Sureka in the India-related governance record.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.